S’pore firms expand product range, enter new markets with help of EnterpriseSG’s scale-up programme

Mirxes co-founder and chief executive Zhou Lihan said that overseas expansion is important because these markets provide growth opportunities. PHOTO: MIRXES

SINGAPORE - Biotechnology firm Mirxes had over 100 employees in 2021. But in just three years, the company has more than doubled in size, with over 300 staff globally today.

The Singapore-headquartered company, which stands on the cutting edge of RNA technology – the same tech used in Covid-19 vaccines – also has physical operations in the US, China, Hong Kong, Japan and South-east Asia, as well as commercial activities in the broader Asia-Pacific markets.

And while it is based here, it keeps a keen eye on the region’s vast potential.

Co-founder and chief executive Zhou Lihan said: “As a first mover in the region’s nascent precision cancer detection market, Mirxes is poised for dominance.”

The firm develops and commercialises accurate, non-invasive and affordable blood tests based on micro-RNA technology for early disease detection, including cancer.

It credits its growth to a programme by Enterprise Singapore (EnterpriseSG) which helps local companies to scale up. Mirxes participated in the programme in 2020 and embarked on a partnership journey with its anchor partner, management consulting firm EY-Parthenon. 

To date, the Scale-Up SG programme, which started in 2019, has supported 92 companies across diverse sectors in mapping out their plans and achieving their growth ambitions, EnterpriseSG said. The programme aims to help high-potential Singapore companies grow further and become global champions.

Companies with global headquarters in Singapore that have demonstrated a strong track record of growth and good leadership bench strength are invited to join the programme by EnterpriseSG. The firms must also have the ambition to take their business global and to transform.

The first three runs involving a total of 47 companies achieved an average revenue growth rate of 68 per cent in just two years. Meanwhile, around half of these 47 firms entered new markets.

About 85 per cent of them have also launched new businesses and products after going through the programme. About a third of them have also expanded through joint ventures and mergers and acquisitions.

EnterpriseSG director of growth enterprise development Lee Meilian said: “Through the programme, companies have worked with different partners and experts to conceptualise strategies to expand into new markets, work on new product offerings, and even develop new business models.”

She added that the agency also provides targeted assistance in areas like the sharing of industry and market insights, providing access to business leads in overseas markets, and customising funding support.

For Mirxes, overseas expansion is important because these markets provide growth opportunities, said Dr Zhou. “We hope to achieve strong in-market relevance, alongside first-mover advantage,” he added.

Mirxes credits its growth to a programme by EnterpriseSG which helps local companies to scale up. PHOTO: MIRXES

He said that the Scale-Up SG programme helped Mirxes to take a deep dive into key South-east Asian markets and truly understand them, such as the type of government support provided, the regulatory environment and potential in-market partners.

“Through these deep dives, we refined some of our market strategies and value propositions. For instance, given the fragmented and nascent but growing molecular diagnostic ecosystem in the South-east Asian countries outside of Singapore, Mirxes adopted a dual approach of providing services and products when entering these markets,” Dr Zhou said.

This dual approach meant that Mirxes designed and launched clinical test offerings through lab-developed tests, while also building capabilities to develop an in-vitro diagnostics product towards regulatory approval at the same time. This meant the firm could capture immediate and longer-term opportunities in each market.

Today, Mirxes is poised for further expansion across South-east Asia.

“Building on our successful clinical laboratory presence in the Philippines, we’re establishing strong partnerships to set up clinical and manufacturing facilities in both Indonesia and Malaysia. This regional focus allows us to tap the vast potential of South-east Asia’s growing healthcare market,” Dr Zhou said.

Other companies that went through the programme also found success in expanding overseas.

Mercantile Pacific vice-chairman and managing director Karan Narula said: “In our opinion, the ingredients for success for our company have been a combination of internationalisation and digitalisation. By expanding into new markets and embracing digital technologies, we have been able to unlock new growth opportunities and stay ahead of market trends.”

Mercantile workers at a factory in Singapore doing tasks such as refurbishment, grading and certification of smart phone devices. PHOTO: MERCANTILE PACIFIC GROUP

The Mercantile group of companies offers solutions for distributing electronic devices and mobile phones, as well as managing the life cycle of information technology products.

It now has a presence in more than 80 markets.

It participated in the programme in November 2022 till January 2024, with McKinsey as its anchor partner. It aims to double or even triple its growth in the next three years.

“Through the Scale-up programme, we have effectively utilised resources to establish an Industry 4.0-enabled refurbishment facility in Dubai,” Mr Narula said.

“This innovative initiative not only refurbishes lower-grade used devices for resale, but also plays a pivotal role in minimising our carbon footprint, thus supporting global decarbonisation endeavours. With an ambitious revenue target of two to three times by the 2026 financial year, we are dedicated to exploring how circularity and sustainability can serve as drivers for business growth while simultaneously advancing environmental objectives.”

Meanwhile, for Rotary, an engineering, procurement, construction and maintenance company, the programme helped to provide clarity on its direction and opportunities to focus on.

Rotary’s completion of two LNG inner mechanical tanks for the PTTLNG Nongfab Terminal in 2022 is testament to its commitment for continuous development in cryogenic capabilities. PHOTO: ROTARY

Through the programme from 2022 to 2023, the firm entered two new markets and four market segments, including new energies and waste-to-energy, which expanded its available market and sales pipeline by over 40 per cent.

It also plans to expand into new markets in the future, especially in the Middle East and North Africa.

“Our aim is to establish connections between traditional energy-producing regions and emerging consumer markets, fostering sustainable growth and development,” said Rotary’s group deputy chairman Grace Chia.

She added that having a clear vision is vital in business.

“Success, in my view, is crafted from a blend of boldness, coordination, urgency, vision and resilience. Having bold aspirations, even if they seemed unconventional at the time, allowed us to push beyond traditional boundaries and expand our horizons exponentially,” she said.

Companies interested in the programme can contact EnterpriseSG at scaleupsg@enterprisesg.gov.sg

Join ST's Telegram channel and get the latest breaking news delivered to you.